Expert Consensus Document: World Heart Federation Expert Consensus Statement on Antiplatelet Therapy in East Asian Patients with ACS or Undergoing PCI

Overview

Journal Nat Rev Cardiol

Specialty Cardiology & Vascular Diseases

Date 2014 Aug 27

PMID 25154978

Citations 124

Authors

Glenn N Levine

Young-Hoon Jeong

Shinya Goto

Jeffrey L Anderson

Yong Huo

Jessica L Mega

Kathryn Taubert

Sidney C Smith Jr

Affiliations

Soon will be listed here.

Abstract

Guideline recommendations on the use of dual antiplatelet therapy (DAPT) in patients with acute coronary syndromes and in those undergoing percutaneous coronary intervention (PCI) have been formulated by both the ACC/AHA and the ESC. These recommendations are based primarily on large, phase III, randomized, controlled trials of the P2Y12 inhibitors clopidogrel, prasugrel, and ticagrelor. However, few East Asian patients have been included in the trials to assess the use of these agents, particularly the newer agents prasugrel and ticagrelor. Additionally, an increasing body of data suggests that East Asian patients have differing risk profiles for both thrombophilia and bleeding compared with white patients, and that a different 'therapeutic window' of on-treatment platelet reactivity might be appropriate in East Asian patients. Furthermore, a phenomenon referred to as the 'East Asian paradox' has been described, in which East Asian patients have a similar or even a lower rate of ischaemic events after PCI compared with white patients, despite a higher level of platelet reactivity during DAPT. Recognizing these concerns, the World Heart Federation has undertaken this evidence-based review and produced this expert consensus statement to determine the antiplatelet treatment strategies that are most appropriate for East Asian patients.

Citing Articles

BMI and Deescalation From Ticagrelor to Clopidogrel in Patients With Acute Myocardial Infarction: A Post Hoc Analysis of the TALOS-AMI Trial.

Bu S, Kim C, Lim S, Jang J, Park M, Choi I JAMA Netw Open. 2025; 8(2):e2461916.

PMID: 40014346 PMC: 11868972. DOI: 10.1001/jamanetworkopen.2024.61916.

Safety Analysis of Spironolactone Use in Patients Undergoing Percutaneous Coronary Intervention with High Bleeding Risk: A Propensity Score-Matched Study.

Zhang J, Yan T, Liu R, Li Y, Zhou M, Wang H Cardiovasc Drugs Ther. 2025; .

PMID: 39907871 DOI: 10.1007/s10557-025-07676-3.

Clinical Outcomes and Safety Profiles of Generic Versus Brand-Name Clopidogrel in Patients Following Coronary Artery Stent Placement.

Chia C, Hsiao F, Hsu T, Tung Y, Lin C, Chu P Clin Transl Sci. 2025; 18(2):e70143.

PMID: 39868895 PMC: 11770885. DOI: 10.1111/cts.70143.

CYP2C19 Genotype-Guided Antiplatelet Therapy and Clinical Outcomes in Patients Undergoing a Neurointerventional Procedure.

Tunehag K, Pearce A, Fox L, Stouffer G, Solander S, Lee C Clin Transl Sci. 2025; 18(1):e70131.

PMID: 39822142 PMC: 11739457. DOI: 10.1111/cts.70131.

The predictive value of the ARC-HBR criteria for in-hospital bleeding risk following percutaneous coronary intervention in patients with acute coronary syndrome.

Liu J, He H, Su H, Hou J, Luo Y, Chen Q Int J Cardiol Heart Vasc. 2024; 55:101527.

PMID: 39498347 PMC: 11533499. DOI: 10.1016/j.ijcha.2024.101527.

References

Wallentin L, Becker R, Budaj A, Cannon C, Emanuelsson H, Held C . Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361(11):1045-57. DOI: 10.1056/NEJMoa0904327. View

Roe M, Armstrong P, Fox K, White H, Prabhakaran D, Goodman S . Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med. 2012; 367(14):1297-309. DOI: 10.1056/NEJMoa1205512. View

Beinart S, Kolm P, Veledar E, Zhang Z, Mahoney E, Bouin O . Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation.... J Am Coll Cardiol. 2005; 46(5):761-9. DOI: 10.1016/j.jacc.2005.03.073. View

Mehta S, Yusuf S, Peters R, Bertrand M, Lewis B, Natarajan M . Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001; 358(9281):527-33. DOI: 10.1016/s0140-6736(01)05701-4. View

Kimura T, Morimoto T, Nakagawa Y, Tamura T, Kadota K, Yasumoto H . Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation. Circulation. 2009; 119(7):987-95. DOI: 10.1161/CIRCULATIONAHA.108.808311. View

Yusuf S, Zhao F, Mehta S, Chrolavicius S, Tognoni G, Fox K . Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001; 345(7):494-502. DOI: 10.1056/NEJMoa010746. View

Tsukahara K, Kimura K, Morita S, Ebina T, Kosuge M, Hibi K . Impact of high-responsiveness to dual antiplatelet therapy on bleeding complications in patients receiving drug-eluting stents. Circ J. 2010; 74(4):679-85. DOI: 10.1253/circj.cj-09-0601. View

Krishna V, Diamond G, Kaul S . Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: the role of platelet reactivity and genotype testing in the prevention of atherothrombotic cardiovascular events remains unproven. Circulation. 2012; 125(10):1288-303. DOI: 10.1161/CIRCULATIONAHA.111.075242. View

Jneid H, Wright R, Adams C, Bridges C, Casey Jr D, Ettinger S . 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/Non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of.... Circulation. 2012; 126(7):875-910. DOI: 10.1161/CIR.0b013e318256f1e0. View

10.

Suh J, Lee S, Park K, Lee H, Kang H, Koo B . Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy.... J Am Coll Cardiol. 2011; 57(3):280-9. DOI: 10.1016/j.jacc.2010.08.631. View

11.

Li H, Butler K, Yang L, Yang Z, Teng R . Pharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: an open-label, sequential, two-cohort, single-centre study. Clin Drug Investig. 2011; 32(2):87-97. DOI: 10.2165/11595930-000000000-00000. View

12.

Bhatt D . Antiplatelet therapy: Ticagrelor in ACS-what does PLATO teach us?. Nat Rev Cardiol. 2009; 6(12):737-8. DOI: 10.1038/nrcardio.2009.192. View

13.

Mahaffey K, Wojdyla D, Carroll K, Becker R, Storey R, Angiolillo D . Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2011; 124(5):544-54. DOI: 10.1161/CIRCULATIONAHA.111.047498. View

14.

Kumar R, Douglas P, Peterson E, Anstrom K, Dai D, Brennan J . Effect of race and ethnicity on outcomes with drug-eluting and bare metal stents: results in 423 965 patients in the linked National Cardiovascular Data Registry and centers for Medicare & Medicaid services payer databases. Circulation. 2013; 127(13):1395-403. DOI: 10.1161/CIRCULATIONAHA.113.001437. View

15.

Scott S, Sangkuhl K, Stein C, Hulot J, Mega J, Roden D . Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013; 94(3):317-23. PMC: 3748366. DOI: 10.1038/clpt.2013.105. View

16.

Kitamura A, Nakagawa Y, Sato M, Iso H, Sato S, Imano H . Proportions of stroke subtypes among men and women > or =40 years of age in an urban Japanese city in 1992, 1997, and 2002. Stroke. 2006; 37(6):1374-8. DOI: 10.1161/01.STR.0000221714.96986.5f. View

17.

Shen A, Yao J, Brar S, Jorgensen M, Chen W . Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol. 2007; 50(4):309-15. DOI: 10.1016/j.jacc.2007.01.098. View

18.

Bhatt D . Prasugrel in clinical practice. N Engl J Med. 2009; 361(10):940-2. DOI: 10.1056/NEJMp0806848. View

19.

Mehta S, Tanguay J, Eikelboom J, Jolly S, Joyner C, Granger C . Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet. 2010; 376(9748):1233-43. DOI: 10.1016/S0140-6736(10)61088-4. View

20.

. 65th World Health Assembly closes with new global health measures. Cent Eur J Public Health. 2012; 20(2):163-4. View